In our study, we utilized 3xTg‐AD mice, which are well‐established animal models that exhibit both amyloid and tau pathology, as well as cognitive deficits, to assess the potential therapeutic effect of FGF10 in vivo (Sterniczuk et al., 2010; Stover et al., 2015). This evidence concerns the gene MAPT and Cognitive impairment.